EMERYVILLE, Calif. and SAN FRANCISCO, Oct. 04, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (AMRS), the industrial bioscience company, in collaboration with the Autodesk BioNano Research Group, today announced the immediate availability of powerful open source tools for genetic design that leverage Autodesk’s Genetic Constructor, an extensible, open source, cloud CAD tool, and Amyris’s open source Genotype Specification Language (“GSL”), to more rapidly drive biological design and complex DNA construction. Autodesk BioNano Research and Amyris will be showcasing this solution today at SynBioBeta SF 2016 in San Francisco.

Best of Both Worlds

Those working in the genetic design community traditionally use a collection of disparate industrial and academic software tools that can be inefficient, difficult to acquire, set up, learn, and use. Genetic Constructor with GSL inside provides a seamless environment combining the power of a written genetic programming language along with an intuitive graphical environment. In the same way that early compilers in the software industry dramatically increased productivity and standardized the field, we expect that enabling everyone to access industrial grade tooling will greatly advance the synthetic biology sector. Industry wide adoption of an efficient common tool set and genetic programming language will benefit everyone.

“Amyris is clearly a leader in high-throughput DNA manufacturing. We are thrilled to enable any biologist to use GSL to ‘code’ their biological designs and we hope Genetic Constructor plus GSL dramatically speeds up the pace of genetic design,” stated Eli Groban, Head of BioNano Research at Autodesk.

“We are extremely pleased that Autodesk BioNano Research has adopted GSL as the first integration of a language for genomic design,” said Joel Cherry, President of Research & Development at Amyris. “Amyris used its deep experience designing DNA to develop a common-sense language for describing genetic designs. Building on notation that is familiar to any geneticist, the GSL compiler translates a request quickly into the information needed to create the DNA.”

Continued Cherry, “Much as standardized computer languages like C revolutionized the early computer industry, we hope to establish GSL as a common industry standard platform. Genetic Constructor is the perfect visual complement to GSL.”

Genetic Constructor started from a collaboration between the Autodesk BioNano Research group and the University of Edinburgh. Autodesk’s BioNano Research Group aims to place the full power of Autodesk software in the hands of scientists, thereby enabling the ability to design on the BioNano scale. This web based, fully extensible, design software, available under an open source license, now incorporates an extension featuring an integrated development environment that is easier for scientists to use in the real-world process of assembling and testing actual, physical DNA coupled with Amyris’s GSL.

Genotype Specification Language (GSL), is a programming language that facilitates the rapid design of large and complex DNA constructs used to engineer genomes. The GSL compiler implements a high-level language based on traditional genetic notation, as well as a set of low-level DNA manipulation primitives. The language allows facile incorporation of parts from a library of cloned DNA constructs and from the “natural” library of parts in fully sequenced and annotated genomes. GSL was designed to engage genetic engineers in their native language while providing a framework for higher level abstract tooling. GSL was developed and open sourced by Amyris.

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.

Amyris, Inc. (NASDAQ:AMRS) shares are moving +20.3721% on the news today and have traded in the range of $0.6411 – 0.7800 during the current trading session. A number of brokerage analysts have recently weighed in on the stock, providing price target projections. The covering firms currently have a consensus one-year price target of $2.6800 on the stock. This is according to brokerage analysts polled by Thomson Reuters First Call. This is the average number from the individual targets provided by the firms. Analysts are projecting earnings per share of $-0.0200 for the next fiscal quarter. For the current year, analysts are predicting earnings of $-0.2000 per share according to First Call.

Are Shares of Amyris, Inc. (NASDAQ:AMRS) Ready to Explode? Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

In looking at where Amyris, Inc. (NASDAQ:AMRS) is trading on a technical level, the stock is trading +58.2297% away from its 50-day moving average of $0.4866. Based on the most recent available data, the equity is -69.4484% off of its 52-week high of $2.5200 and +148.3548% away from its 52-week low which is $0.3100

Today, the stock opened at $0.6518 and the last bid at the time of writing stood at $0.7699. During the session thus far, the equity dipped down to $0.6411 and touched $0.7800 as the high point. Amyris, Inc. (NASDAQ:AMRS) has a market cap of $180.94M and has seen an average daily volume of 2636100 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information. Assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.